Skip to main content
    T

    Tenaya Therapeutics Inc (TNYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.33
    -0.02 (-4.47%)

    Market Cap: $79.59M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Tenaya Therapeutics Inc (TNYA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Tenaya Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$90.60M, operating cash flow was -$68.26M and free cash flow was -$68.88M. The quarter ended Sep 30, 2026 had revenue of $1.70M and net income of -$18.94M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $93.33M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$8.44M$0$0$0$0$0$1.99M
    Gross profit-$8.44M$0$0$0$0$0-$1.99M
    Research and development$68.61M$86.74M$98.04M$94.54M$54.39M$31.10M$23.15M
    Operating income-$93.33M-$115.95M-$131.19M-$125.62M-$72.81M-$38.91M-$27.71M
    Net income-$90.60M-$111.13M-$124.08M-$123.67M-$72.72M-$38.40M-$25.78M
    EBITDA-$82.16M-$107.58M-$122.14M-$119.46M-$69.74M-$36.00M-$25.72M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.70M$1.11M$225.00K$0$0$0$0$0$0$0$0$17.66M
    Gross profit$1.70M$1.11M$225.00K$3.95M$0$0$0N/A$0$0$0-$2.99M
    Operating income-$19.57M-$44.09M-$20.07M-$20.77M-$20.94M-$24.08M-$27.54M-$24.65M-$26.71M-$30.82M-$33.76M-$31.45M
    Net income-$18.94M-$43.39M-$19.27M-$20.18M-$20.27M-$23.28M-$26.86M-$23.84M-$25.63M-$29.43M-$32.23M-$29.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.02M by $97.53M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$146.92M$119.94M$170.51M$278.94M$314.19M$148.16M$38.00M
    Current assets$105.59M$67.38M$111.58M$193.75M$255.36M$129.96M$27.74M
    Cash and equivalents$100.55M$4.32M$45.68M$95.27M$38.13M$128.53M$23.87M
    Total liabilities$23.66M$27.09M$31.09M$35.57M$35.66M$8.72M$81.74M
    Short-term debt$3.02M$2.78M$4.32M$4.01M$1.99MN/AN/A
    Shareholder equity$123.27M$92.85M$139.42M$243.38M$278.53M-$81.31M-$43.74M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$76.68M$93.54M$135.07M$146.92M$104.98M$122.15M$143.95M$119.94M$140.58M$163.19M$184.90M$170.51M
    Total liabilities$22.16M$24.13M$28.88M$23.66M$22.11M$22.32M$24.56M$27.09M$27.98M$29.19M$26.72M$31.09M
    Cash and equivalents$66.80M$78.08M$80.89M$100.55M$56.31M$62.67M$53.77M$4.32M$8.23M$58.13M$59.30M$45.68M
    Shareholder equity$54.52M$69.41M$106.19M$123.27M$82.87M$99.83M$119.40M$92.85M$112.60M$134.00M$158.18M$139.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$68.26M-$90.50M-$102.07M-$104.42M-$60.81M-$35.45M-$24.10M
    Capital expenditures$618.00K$1.02M$1.24M$20.63M$25.12M$9.76M$2.93M
    Free cash flow-$68.88M-$91.53M-$103.31M-$125.05M-$85.93M-$45.21M-$27.02M
    Share repurchasesN/A$0$501.00K$0$13.00K$1.00KN/A
    Investing cash flow$56.08M$1.13M$48.72M$83.65M-$238.56M-$7.01M-$5.58M
    Financing cash flow$108.41M$47.75M$4.05M$77.77M$208.97M$147.27M$30.51M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$17.68M-$3.55M-$19.23M-$13.94M-$15.60M-$15.61M-$23.11M-$18.39M-$19.84M-$23.62M-$28.66M-$21.92M
    Capital expendituresN/A$159.00K$11.00K$67.00K$26.00K$142.00K$383.00K$204.00K$184.00K$73.00K$564.00K$394.00K
    Free cash flowN/A-$3.71M-$19.25M-$14.01M-$15.63M-$15.76M-$23.50M-$18.59M-$20.02M-$23.69M-$29.22M-$22.32M
    Last 12 quarters

    Frequently Asked Questions About TNYA

    What is Tenaya Therapeutics' annual revenue?

    Tenaya Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Tenaya Therapeutics profitable?

    No. Tenaya Therapeutics reported net income of -$90.60M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TNYA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$68.26M minus capital expenditures of $618.00K produced free cash flow of -$68.88M.

    How much debt does Tenaya Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.02M and cash and equivalents of $100.55M.